Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Stent price control...

    Stent price control will save patients Rs 4,450 crore: Govt

    Written by savita thakur thakur Published On 2017-03-18T09:55:55+05:30  |  Updated On 18 March 2017 9:55 AM IST
    Stent price control will save patients Rs 4,450 crore: Govt

    NEW DELHI: The price control of stents will result in annual savings of about Rs 4,450 crore for patients, Parliament was informed.


    "After the inclusion of coronary stents in the Schedule I of DPCO 2013 on December 21, 2016, the prices were fixed by the NPPA on February 12, 2017, which will result in approximate annual savings of about Rs 4,450 crore to patients," Minister of State for Chemicals Mansukh L Mandaviya said in a written reply to the Lok Sabha.

    The National Pharmaceutical Pricing Authority (NPPA) had notified the ceiling price of coronary stents at Rs 7,260 for bare metal stent and Rs 29,600 for drug-eluting ones.

    The corresponding average MRPs before the notification stood at Rs 45,100 and Rs 1.21 lakh.

    "Price regulation has brought down the prices of bare metal stent by 74 per cent and that drug-eluting stents by 85 per cent," the minister said.

    In a separate reply, the minister said the NPPA has directed hospitals to issue detailed bills to patients, specifically and separately mentioning cost of the coronary stents along with brand name of manufacturer or importer and other details.

    Non-adherence to the rules will be treated as deliberate distortion of evidence along with charges of overpricing inviting prosecution under the Essential Commodities Act, Mandaviya added.

    Besides, the government through the NPPA is keeping a tab and has alerted the states and state drug controllers to monitor the availability of stents, he said.

    "Industry has been apprised that all manufacturers, importers are under legal obligation to maintain smooth production and supply of coronary stents of all brands which were available in the country before price cap," the minister said.

    NPPA already has conducted two rounds of discussions with the stent companies which in turn have promised required level of availability.
    IndiaMansukh L MandaviyaNational Pharmaceutical Pricing AuthorityNPPAStentStent price
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok